USITC to probe alleged engineered-rice theft by Chinese company
The US International Trade Commission (ITC) is to investigate allegations that a Chinese company infringed patents held by Ventria Bioscience by importing genetically-engineered rice seeds for medical purposes.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
28 November 2022 German biopharma company’s complaint against Palo Alto competitor prompts commission to investigate | Patents in dispute relate to bio-layer interferometry.
20 October 2022 Commission overturns one ALJ finding but affirms all others, agreeing that Wuhan Healthgen infringed Ventria's rice seed patent | Dispute concerns recombinant human proteins derived from genetically engineered rice.
15 September 2022 Kansas-based company wins block on infringing plant-based albumins | Genetically programmed rice expresses human proteins used in immunotherapy drugs, gene therapies and vaccines.